Chinese Journal of Integrative Medicine

, Volume 21, Issue 1, pp 71–79 | Cite as

Shenqi Fuzheng Injection (参芪扶正注射液) for advanced gastric cancer: A systematic review of randomized controlled trials

  • Jiang Li (李 江)
  • Jian-cheng Wang (王建成)
  • Bin Ma (马 彬)
  • Wei Gao (高 伟)
  • Peng Chen (陈 鹏)
  • Rao Sun (孙 绕)
  • Ke-hu Yang (杨克虎)Email author
Evidence-Based Integrative Medicine



To evaluate the effectiveness of Shenqi Fuzheng Injection (参芪扶正注射液, SFI) combined with chemotherapy for advanced gastric cancer.


Randomized controlled trials (RCTs) from 10 databases were searched for this meta-analysis till December 31, 2012 without language restriction. Grey literature and potential unpublished literature was also searched. The key search terms were “chemotherapy”, “Shenqi Fuzheng Injection” and “advanced gastric cancer”. Criteria were built to select these clinical trials, in which SFI combined with chemotherapy was compared with chemotherapy alone for advanced gastric cancer. The methodological quality of each RCT was assessed using the Cochrane risk of bias tool. RevMan 5.1 software was applied for data analyses.


Thirteen RCTs involving 860 patients met the selection criteria (all articles were from Chinese databases). The meta-analysis showed positive results for the use of SFI combined with chemotherapy according to quality of life in terms of the scores when compared with chemotherapy alone. Positive results were also obtained for the combination treatment, in terms of complete remission and partial remission efficacy rate, body weight and decreased adverse events including nausea and vomiting at grade 3–4, oral mucositis at grade 1–2, leucopenia at grade 3–4, and myelo-suppression at grade 1–2.


This systematic review found encouraging albeit limited evidence for SFI combined with chemotherapy. However, to obtain stronger evidence without the drawbacks of trial design and the quality of studies, we recommend comparative effectiveness researches to test the effectiveness of combination treatment.


chemotherapy Shenqi Fuzheng Injection advanced gastric cancer Chinese medicine systematic review randomized controlled trial 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Wagner AD, Moehler M. Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era. Curr Opin Oncol 2009;21:381–385.PubMedCrossRefGoogle Scholar
  2. 2.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69–90.PubMedCrossRefGoogle Scholar
  3. 3.
    Forman D, Burley VJ. Gastric cancer: global pattern of the disease and an overview of environmental risk factors. Best Pract Res Clin Gastroenterol 2006;20:633–649.PubMedCrossRefGoogle Scholar
  4. 4.
    Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999;49:33–64.PubMedCrossRefGoogle Scholar
  5. 5.
    Sun DZ, Jiao JP, Ju DW, Ye M, Zhang X, Xu JY, et al. Tumor interstitial fluid and gastric cancer metastasis: an experimental study to verify the hypothesis of “tumor-phlegm micro-environment”. Chin J Integr Med 2012;18:350–358.PubMedCrossRefGoogle Scholar
  6. 6.
    Park JW, Yoon J, Cho CK, Lee YW, Yoo HS. Survival analysis of stage IV metastatic gastric cancer patients treated with HangAm-Plus. Chin J Integr Med 2014;20:49–55.PubMedCrossRefGoogle Scholar
  7. 7.
    Roy A, Cunningham D, Hawkins R, Sörbye H, Adenis A, Barcelo JR, et al. Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophagogastric cancer: a randomised phase II study. Br J Cancer 2012;107:435–441.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Hermans J, Bonenkamp JJ, Boon MC, Bunt AM, Ohyama S, Sasako M, et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 1993;11:1441–1447.PubMedGoogle Scholar
  9. 9.
    Yeh JM, Hur C, Kuntz KM, Ezzati M, Goldie SJ. Costeffectiveness of treatment and endoscopic surveillance of precancerous lesions to prevent gastric cancer. Cancer 2010;116:2941–2953.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
  11. 11.
    Dharmananda S. Kampo medicine: the practice of Chinese herbal medicine in Japan. Portland, OR: Institute for Traditional Medicine; 2001.Google Scholar
  12. 12.
    Chen Z, Gu K, Zheng Y, Zheng W, Lu W, Shu XO. The use of complementary and alternative medicine among Chinese women with breast cancer. J Altern Complement Med 2008;14:1049–1055.PubMedCrossRefGoogle Scholar
  13. 13.
    McCulloch M, See C, Shu XJ, Broffman M, Kramer A, Fan WY, et al. Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. J Clin Oncol 2006;24:419–430.PubMedCrossRefGoogle Scholar
  14. 14.
    Pan CX, Morrison RS, Ness J, Fugh-Berman A, Leipzig RM. Complementary and alternative medicine in the management of pain, dyspnea, and nausea and vomiting near the end of life. A systematic review. J Pain Symptom Manage 2000;20:374–387.PubMedCrossRefGoogle Scholar
  15. 15.
    Lu Y, Lu YX. Clinical application and pharmacology function of Shenqi Fuzheng Injection. Lishizhen Med Mater Med Res (Chin) 2006;17:2083–2085.Google Scholar
  16. 16.
    Sheng S, Song M. The component analysis of Shengqi Fuzheng Injection. J China Prescript Drug (Chin) 2004;8:47–49.Google Scholar
  17. 17.
    Pan L. Practical road of “the numeral turn Chinese herbal medicine” for Shenqi Fuzheng Injection. J China Prescript Drug (Chin) 2009;1:37–39.Google Scholar
  18. 18.
    Zhong ZH. Dictate history: a national new medicine that come from experiential prescription. J China Prescript Drug (Chin) 2009;1:33–36.Google Scholar
  19. 19.
    Hollen PJ, Gralla RJ, Kris MG, Cox C, Belani CP, Grunberg SM, et al. Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the Lung Cancer Symptom Scale. Cancer 1994;73:2087–2098.PubMedCrossRefGoogle Scholar
  20. 20.
    Zhou HJ, So JB, Yong WP, Luo N, Zhu F, Naidoo N, et al. Validation of the functional assessment of cancer therapy—gastric module for the Chinese population. Health Qual Life Outcomes 2012;10:145.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    National Cancer Institute. Common terminology criteria for adverse events and common toxicity criteria. Version 4.0. Bethesda: NCI; 2010. Scholar
  22. 22.
    Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1–12.PubMedCrossRefGoogle Scholar
  23. 23.
    Jüni P, Altman DG, Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ 2001;323:42–46.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924–926.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in metaanalyses? Lancet 1998;352:609–613.PubMedCrossRefGoogle Scholar
  26. 26.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–188.PubMedCrossRefGoogle Scholar
  27. 27.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557–560.PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from Scholar
  29. 29.
    Fang XY. Observation of efficacy of Shenqi Fuzheng Injection combined with FOLFOX4 chemotherapy in treatment of advanced gastric cancer. Chin J Pract Med (Chin) 2010;37:23–24.Google Scholar
  30. 30.
    Jia JW, Liu YQ. Effect of Shenqi Fuzheng Injection combined with FOLFOX4 regimen in the treatment of advanced gastric cancer. Pract J Cancer (Chin) 2009;24:273–275.Google Scholar
  31. 31.
    Li ZY, Huang QH, Xu HS, Ruan XF. The efficacy of Shenqi Fuzheng Injection combined with chemotherapy in gastric cancer. J Liaoning Univ Tradit Chin Med (Chin) 2006;8:26–27.Google Scholar
  32. 32.
    Liu H, Han D. Effects of Shenqi Fuzheng Injection on the immunolologic function and clinic efficacy in the elderly patients with advanced gastric cancer. Chin J Clin Pharmacol (Chin) 2011;27:177–183.Google Scholar
  33. 33.
    Luo PF. The efficacy of Shenqi Fuzheng Injection combination chemotherapy for advanced gastric cancer. Modern Med Health (Chin) 2011;27:1170–1171.Google Scholar
  34. 34.
    Wan LX, Wang Y. Shenqi Fuzheng Injectiong combined with FOLFOX4 for advanced gastric cancer. J Med Forum (Chin) 2006;27:96–97.Google Scholar
  35. 35.
    Wang JF. Shenqi Fuzheng Injection combined chemoradiotherapy treatment of locally advanced gastric cancer. Chin Med Sci Technol (Chin) 2010;17:537–538.Google Scholar
  36. 36.
    Wang M, Lin HJ. Efficacy observation of Shenqi Fuzheng Injection combined with FOLFOX4 chemotherapy in treatment of advanced gastric cancer. Drugs Clin (Chin) 2011;18:89–90.Google Scholar
  37. 37.
    Wang YS, Shi ZX, Guo YH. Shenqi Fuzheng Injection combination chemotherapy for elderly patients with advanced gastric cancer. Med J West Chin (Chin) 2011;23:1958–1959.Google Scholar
  38. 38.
    Xiong W. The efficacy Shenqi Fuzheng Injection with DCF chemotherapy in advanced gastric cancer. Guangming Chin Med (Chin) 2010;25:635–636.Google Scholar
  39. 39.
    Yue CL. Clinical observation of chemotherapy combined with Shenqi Fuzheng Injection treating gastric cancer. Chin New Med (Chin) 2003;4:1063–1064.Google Scholar
  40. 40.
    Zhao JM, Wu AZ, Shi LR, Yang XX, Li JH, Wu CP. Clinical observation on treatment of advanced gastric cancer by combined use of Shenqi Fuzheng Injection, docetaxel, flurouracil and calcium folinate. Chin J Integr Tradit West Med (Chin) 2007;27:736–738.Google Scholar
  41. 41.
    Zhou KX, Wang JH, Liu BK, Zhou CY, Xin M, Zhi JL, et al. Clinical study on effect of Shenqi Fuzheng Injection combined with chemotherapy in treating gastric cancer. Chin J Integr Tradit West Med (Chin) 1999;19:11–13.Google Scholar
  42. 42.
    Shao BM, Xu W, Dai H, Tu P, Li Z, Gao XM. A study on the immune receptors for polysaccharides from the roots of Astragalus membranaceus, a Chinese medicinal herb. Biochem Biophys Res Commun 2004;320:1103–1111.PubMedCrossRefGoogle Scholar
  43. 43.
    Schulz KF, Grimes DA. Allocation concealment in randomised trials: defending against deciphering. Lancet 2002;359:614–618PubMedCrossRefGoogle Scholar

Copyright information

© Chinese Association of the Integration of Traditional and Western Medicine and Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Jiang Li (李 江)
    • 1
    • 2
    • 3
  • Jian-cheng Wang (王建成)
    • 1
    • 2
    • 3
  • Bin Ma (马 彬)
    • 1
    • 2
    • 3
  • Wei Gao (高 伟)
    • 4
  • Peng Chen (陈 鹏)
    • 5
  • Rao Sun (孙 绕)
    • 1
    • 2
  • Ke-hu Yang (杨克虎)
    • 1
    • 2
    • 3
    Email author
  1. 1.Evidence-Based Medicine Center, College of Basic MedicineLanzhou UniversityLanzhouChina
  2. 2.Institute of Integrated Traditional Chinese and Western Medicine, College of Basic MedicineLanzhou UniversityLanzhouChina
  3. 3.Key Laboratory of Evidence-Based Medicine and Knowledge Translation of Gansu ProvinceLanzhouChina
  4. 4.Department of Internal MedicineUniversity of California Davis Medical CenterSacramentoUSA
  5. 5.First School of Clinical MedicineGuangzhou University of Chinese MedicineGuangzhouChina

Personalised recommendations